Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.

Science translational medicine - 12 Aug 2026

Song Huaxin, Chen Xinjie, Xiao Shujun, Wu Jiaqi, Dai Yuting, Wu Wen, Wu Yu, Weng Xiangqin, Song Jiachun, Yan Ni, Ye Chenjing, Shi Fangfang, Cui Jingyi, Zheng Derun, Zhang Hesong, Tan Kai, Chen Xueqin, Zhang Sujiang, Wu Jiale, Lu Min

Abstract excerpt

Acute myeloid leukemia/myelodysplastic syndromes (AML/MDSs) carrying p53 mutations are refractory to various standard therapies. Arsenic trioxide (ATO) may be effective in restoring function to p53 structural mutants. Here, we report that mutant p53 rescued by ATO treatment strengthened interferon responses triggered by the DNA hypomethylating agent decitabine by transactivating interferon regulatory factor 7...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Cell Line, Tumor

Share to Decitabine

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 42585289
DOI: 10.1126/scitranslmed.ads9325

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.PMID 42585289Read ↗

Molecular and Clinical Insights into TP53-Mutated MDS and AML.Semantic proximity Read ↗

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.Semantic proximity Read ↗

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

p53 biology and reactivation for improved therapy in MDS and AMLSemantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).Semantic proximity Read ↗

Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.Semantic proximity Read ↗

[Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].Semantic proximity Read ↗

Comparison of<i>TP53</i>Mutations in Myelodysplasia and Acute Leukemia Suggests Divergent Roles in Initiation and ProgressionSemantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.